The Cell Surface Expression of SAP-binding Receptor CD229 Is Regulated via Its Interaction with Clathrin-associated Adaptor Complex 2 (AP-2)*

Juana M. Del ValleDagger, Pablo Engel, and Margarita Martín§

From the Immunology Unit, Department of Cellular Biology and Pathology, University of Barcelona School of Medicine, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona E-08036, Spain

Received for publication, February 13, 2003, and in revised form, February 26, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CD229 (Ly9) is a cell surface receptor selectively expressed on T and B lymphocytes, and it belongs to the CD150 receptor family. Like other receptors of this family, CD229 interacts with SAP/SH2D1a protein, mutation of which is responsible for the fatal X-linked lymphoproliferative disease. Receptors of the CD150 family function as costimulatory molecules, regulating cytokine production and cytotoxicity. Thus, their signaling and regulation in lymphocytes may be critical to an understanding of the pathogenesis of the X-linked lymphoproliferative disease. Here we show that CD229 interacts with the µ2 chain of the AP-2 adaptor complex that links transmembrane proteins to clathrin-coated pits. CD229 was the only member of the CD150 family associated with AP-2. We also show that the µ2 chain interacts with the Y470EKL motif of CD229. The integrity of this site was necessary for CD229 internalization, but it was not involved in SAP recruitment. Moreover, CD229 binds to the AP-2 complex in T and B cell lines, and it is internalized rapidly from the cell surface on T cells after antibody ligation. In contrast, cross-linking of CD229 receptors with intact antibody inhibited CD229 internalization on B cells. However, when F(ab')2 antibodies were used, CD229 internalization was similar on T and B cells, suggesting that Fcgamma receptors control CD229 cell surface expression. Furthermore, CD229 was regulated by T cell receptor and B cell receptor signaling because coligation with antibodies against anti-CD3 and anti-IgM increased the rate of CD229 endocytosis. These data suggest that CD229 cell surface expression on lymphocytes surface is strongly and differentially regulated within the CD150 family members.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CD229 (also termed Ly9) is a cell surface glycoprotein of relative mass 120 kDa found on T and B cells (1). It is a member of the immunoglobulin superfamily, and it belongs to the CD150 family of receptors (2, 3). Six members of the CD150 family (CD150, CD229, CD84, CD244, NTB-A, and CS1) have one or more cytoplasmic tyrosine motifs with the consensus sequence Thr-(Ile/Val)-Tyr(P)-X-X-(Ile/Val). This motif functions as a docking site for the SAP1/SH2D1a protein (4-9). Mutations on the SAP gene, sh2d1a, are the responsible for the fatal X-linked lymphoproliferative disease after Epstein-Barr virus infection, familial hemophagocytic lymphohistiocytosis, and some cases of combined variable immunodeficiency (2, 4, 10-12). These disease phenotypes point to distinct roles for the six CD150 family/SAP signaling pathways in the control of T, B, and natural killer cell activation and homeostasis. Studies on SAP knock-out mice reveal that T cells have an impaired ability to differentiate into T helper 2 cells, resulting in increased resistance to T helper 2-mediated disease such as infection with Leishmania major. In addition, SAP-/- mice fail to resolve the lymphocytic choriomeningitis virus, showing an increased number of interferon-gamma -producing cells in the spleen and liver (13) and a nearly complete absence of virus-specific long lived plasma cells and memory B cells (14). Altogether, these data indicate that SAP controls several distinct key T cell signal transduction pathways, which may be controlled differentially by the various CD150 receptors. It is crucial to elucidate the contribution of each member to these immune functions. Unlike other CD150 family members, CD229 has four rather than two extracellular Ig domains. Domains 1 and 3 are similar, as are domains 2 and 4, suggesting that CD229 arose from a progenitor with two domains (15). Although the function of CD229 is unknown, other members of the subfamily such as CD84, CD244, and CD150 are known to activate lymphocytes (16-22), suggesting that the CD229 molecule is also involved in leukocyte activation. Recently, NTB-A and CS1 have also been shown to regulate cytotoxicity in natural killer cells (23, 24).

In this study, we have investigated the biochemical mechanism involved in CD229 signaling and intracellular trafficking by identifying proteins that interact with the CD229 cytoplasmic domain. Two clones encoding human AP-2 µ2 chain were isolated using CD229 as bait in a three-hybrid screen of a human B cell library. µ2, also termed AP50, is the 50-kDa subunit of the AP-2 complex. AP-2 is a key component of the endocytic machinery that links cargo membrane proteins to the clathrin lattice. It is a heterotetramer consisting of two large (100-115 kDa) alpha  and beta  subunits or adaptins, one medium µ2 (50 kDa), and one small (17 kDa) sigma 2 subunit. The alpha -adaptin appears to contain the major membrane binding interface. The hinge domain of the beta  subunit binds to the clathrin heavy chain, providing a mechanism for the formation of polyhedral lattices. In addition to its structural role in coat assembly, AP-2 is also involved in the transport of proteins from the plasma membrane to the endosomal and lysosomal compartments. For effective cargo into coated pits, receptors should contain specific internalization signals, namely tyrosine-based motifs such as NPXY or YXXphi (where X stands for any amino acid and phi  for a bulky hydrophobic residue), dileucine motifs, and acidic clusters (25, 26). The structural analysis of the AP-2 core reveals that the binding site for YXXphi endocytic motifs is buried, indicating that a conformational change, probably triggered by phosphorylation in the disordered µ2 linker, is necessary to allow YXXphi motif binding (27). Here, we demonstrate that the only member of the CD150 family which specifically binds µ2 is CD229. We mapped the CD229-µ2 interaction in Tyr470 of the CD229 cytoplasmic domain. Moreover, we show that TCR and BCR signaling regulates CD229 expression.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Reagents-- COS-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Jurkat and Daudi cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Biotin, brefeldin A (BFA), and anti-mouse IgG peroxidase were obtained from Sigma. Monoclonal anti-alpha -adaptin AP-2 (clone 100/2), also from Sigma, was used for immunoblotting. Rabbit anti-rat AP-2alpha -C, from Upstate Biotechnology (Lake Placid, NY), was used for immunoprecipitation and microscopy. Phosphotyrosine monoclonal antibody mixture horseradish peroxidase-conjugated was from Zymed Laboratories Inc. (San Francisco). Anti-GFP monoclonal was from Roche Applied Science. Anti-CD84 (clone CD84 1.1), generated at our laboratory (16), was used as a control IgG. Anti-human CD3 (clone T3b) was a gift from Dr. Lopez-Botet (UPF, Barcelona). Anti-human IgM F(ab')2 was from Caltac Laboratories (Burlingame, CA). Anti-CD71 was a gift from Dr. Ramon Vilella (Hospital Clínic, Barcelona). Streptavidin-PE was obtained from BD Pharmingen (San Diego). Steptavidin-Cy3 and anti-rabbit peroxidase were from Dako (Carpinteria, CA). Avidin-peroxidase was purchased from Roche Applied Science.

Anti-human CD229 (clone HLy-9.1.25) was generated at our laboratory (1). Biotinylated anti-CD229 was generated using EZ-Link biotinylation kit from Pierce. F(ab')2 anti-CD229 was prepared using immobilized ficin from Pierce. The purity of the F(ab')2 preparation was confirmed by SDS-PAGE under nonreducing conditions and reducing conditions followed by silver staining.

Yeast Three-hybrid Screen-- The cytoplasmic tail of human CD229, cloned in pBridge and transformed in the yeast strain CG1945, was used as bait to screen a human B cell cDNA library in pACT2 vector (Clontech, Palo Alto, CA). CD229 and mutated Fyn were inserted in the bicistronic vector pBridge. In mutant Fyn, the regulatory tyrosines 420 and 531 were replaced by phenylalanine, and arginine was replaced by glutamine (FynY420F,Y531F,R176Q) as described elsewhere (7).

For the three-hybrid screen in the presence of FynY420F,Y531F,R176Q, the yeast strain CG1945 was cotransformed sequentially with the vector (pBridge), containing both CD229 and the Fyn mutant, and these transformants were selected on SD medium lacking tryptophan and transformed further with 1 mg of the human B cell cDNA library. Double transformants were then plated in SD medium lacking tryptophan, leucine, histidine, and methionine in the presence of 3 mM 3-aminotriazole.

Yeast clones that grew in these restrictive conditions were then tested by the beta -galactosidase assay. DNA was extracted from the beta -galactosidase-positive clones and then expanded after transformation of HB101 bacteria and selection in M9 medium, lacking leucine, to isolate the GAL4 activation domain plasmid pACT2. Purified plasmids were sequenced.

The beta -galactosidase colony-lift filter assay and liquid culture assay using o-nitrophenyl beta -D-galactopyranoside as a substrate were carried out as described in the Clontech yeast protocols handbook. The vector pBridge containing CD229, in the absence of catalytic activity of mutated Fyn, was generated after BglII digestion, ligation, and purification.

Plasmid Constructions-- CD229 cloned in pCIneo was used as a template (1) to generate two mutated DNA sequences of human CD229 (mutants CD229Y470F and CD229Y470A). The primers used to generate all the mutations were: 5'-CTCCCAAGGATTTGAGAAGCTGG-3' (primer 1), 5'-GTGTCCAGCTTCTCAAATCCTTGGG-3' (primer 2), 5'-CTCCCAAGGAGCTGAGAAGCTGG-3' (primer 3), and 5'-CCAGCTTCTCAGCTCCTTGGGAG-3' (primer 4). Construct CD229Y470F was generated using primers 1 and 2, and CD229Y470A using primers 3 and 4. PCR products were cloned using the TOPO subcloning kit (Invitrogen) and sequenced. For expression in yeast, cytoplasmic tails of CD229WT and CD229Y470F were generated from CD229WT and CD229Y470F templates using sense primer 5'-GGGGAATTCAAGCGAAAAGGACGG-3' and antisense primer 5'-GGGGGATCCGGTGAAATTT TCATAGC-3' and subcloned in the pBridge binding domain vector using the EcoRI/BamHI sites.

To generate µ2-EGFP fusion protein, µ2 was amplified by PCR using a cDNA peripheral blood lymphocyte library as a template with sense primer 5'-AAACTGCAGGCCGCCATGATTGGAGGCTTATTC-3' and antisense primer 5'-TTCCCCGGGGCGAGTTTCATAAATGCCACTGCGG-3' and cloned in-frame into the pEGFP-N2 vector (Clontech) using the PstI/SmaI sites. The presence of desired nucleotide changes was established by bidirectional nucleotide sequencing using dye terminator chemistry (PE Biosystems, Foster City, CA).

Transfections-- COS-7 cells (1 × 106) were seeded into 100-mm dishes and 24 h later transfected with 4 µg of each plasmid DNA/dish using the LipofectAMINE Plus kit (Roche Applied Science) following the manufacturer's instructions. Cells were incubated for 48 h, and the experiments were performed.

Immunoprecipitation and Immunoblotting-- Transfected COS-7 cells were biotinylated and lysed with 1% CHAPS (Pierce), and immunoprecipitation was carried out using antibodies against CD229. Likewise, previously biotinylated Jurkat and Daudi cells (100 × 106) were lysed with 1% Triton X-100 as described elsewhere (7). Briefly, cell lysates were precleared for 1 h with 50 µl of protein A-Sepharose beads (Amersham Biosciences). Immunoprecipitations were performed using 2 µg of each indicated antibody, and 40 µl of protein A-Sepharose beads was added for 2 h at 4 °C. Beads were then washed, and samples were boiled. All of the precipitates were separated by SDS-PAGE. Proteins were transferred onto nitrocellulose membranes (Millipore, Bedford, MA). Filters were blocked for 1 h with 5% skim milk (or 3% bovine serum albumin) and then probed with the indicated antibodies. Bound antibody was detected using horseradish peroxide-conjugated secondary antibodies and enhanced chemiluminescence (Pierce).

Internalization Assay-- Cells (1 × 106/sample) were incubated with anti-human CD229 mAb (1 µg/ml = 1 × 106) at 37 °C. At various time points (0-90 min), cells were chilled rapidly and acid stripped to remove cell surface-bound mAb as described elsewhere (28). Samples were washed twice in cold complete culture medium, and they were incubated for 25 min with biotinylated anti-CD229 followed by avidin-PE incubation (1). For recycling experiments, cells were incubated at 37 °C with anti-CD229 in the presence or absence of BFA at 10 µg/ml in complete culture medium for the indicated time periods. Samples were stripped and stained with biotin-conjugated anti-human CD229 followed by streptavidin-PE. For stimulation, cells were treated for 5 min with anti-CD3 or anti-IgM. Intact anti-CD229 or F(ab')2 was added for an additional 30 min. Thereafter, cells were harvested, chilled, and acid stripped as described above. The samples were analyzed in a flow cytometer (FACS Caliber; BD Biosciences, Mountain View, CA) to detect PE (FL2) fluorescence (mean fluorescence intensity; MFI). The percentage of endocytosis was calculated using MFI values of PE as follows: 100 - [(MFI at 37 °C/MFI at 4 °C) × 100].

Immunofluorescence Microscopy-- COS-7 cells were cultured on coverslips, transfected with µ2-EGFP cDNA, fixed, and permeabilized with -20 °C methanol for 15 min. After two washes, they were incubated for 30 min at room temperature with blocking buffer (phosphate-buffered saline containing 0.2% skim milk, 2% fetal bovine serum, 1% bovine serum albumin, 0.1 mM glycine). Cells were then washed and incubated with 2 µg/ml rabbit anti-rat AP-2alpha -C for 1 h at 4 °C. After three washes, they were incubated with a biotinylated anti-rabbit (Biogenex, San Ramon, CA) at 4 °C for 30 min. After several additional washes, cells were incubated with streptavidin-Cy3 (Jackson Immunoresearch, West Grove, PA) at 4 °C for 20 min. Samples were washed and mounted in Fluoromount-G (Southern Biotechnology, Birmingham, AL). For endocytosis experiments, COS-7 cells were cultured on coverslips and cotransfected with human CD229 (WT or Y470F or Y470A mutants) with µ2-EGFP cDNAs in duplicate. After 48 h they were labeled with 1 µg/ml biotinylated mAb CD229 at 4 °C for 30 min. After two washes with ice-cold phosphate-buffered saline, samples were incubated with streptavidin-Cy3 at 37 °C (to induce endocytosis) for 30 min. Cells were then washed and fixed in -20 °C methanol for 15 min. After washing them twice, cells were mounted and visualized as described above. Fluorescence images were obtained using a confocal microscope (TCS NT; Leica, Heidelberg, Germany).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CD229 Interacts with µ2 in a Yeast Three-hybrid Screen-- The cytoplasmic tail of human CD229 was used as bait to screen a human B cell library. The CD229 cytoplasmic tail was cloned in the pBridge vector together with Fyn (7). The screening of ~2 × 106 clones yielded two clones that encoded portions of human µ2, the medium chain of clathrin-associated coated pit adaptor protein complex AP-2 (Fig. 1A). Because the µ2 interaction with proteins is independent of phosphorylation, we assayed the binding by depleting the catalytic activity of Fyn. CD229 binding to µ2 was similar in the presence and absence of kinase activity (Fig. 1B).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   CD229 interacts with µ2 in a three-hybrid screen in yeast. A, the sequence obtained in the two positive clones overlaps (in bold) with the amino acidic sequence of the µ2 (AP50) subunit of the human AP-2 complex. B, beta -galactosidase semiquantitative assay after cotransfection of pBridge CD229 (+Fyn) or (-Fyn) and clone 1.

CD229 Is the Only Member of the CD150 Family of Receptors That Interacts with µ2-- We assayed the interaction of µ2 with all of the CD150 members using a semiquantitative beta -galactosidase assay. All bound to SAP/SH2D1a when Fyn was active, with the exception of CD150, which bound to SAP regardless of its phosphorylation status, as reported elsewhere (29) (Fig. 2A). Surprisingly, only CD229 was able to bind to µ2 in conditions where Fyn was present or absent, whereas the rest of members failed to do so (Fig. 2B).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   CD229 is the only member of the CD150 family which interacts with µ2. Yeast cotransfected with pBridge cytoplamic tails of CD150 family members (CD150, CD244, CD229, CD84, NTB-A, and CS1) +/-Fyn and pGAD-SAP (A) or pACT2-µ2 (B) were analyzed for beta -galactosidase activity. These data are the mean of duplicates and representative of three experiments.

CD229 Binds to µ2-EGFP Chimera and Integrates in AP-2 Endogenous Complex in COS-7 Cells-- To test the interaction CD229-µ2 in a mammal system, we made the µ2-EGFP construct and transiently transfected COS-7 cells alone or together with CD229. To determine whether CD229 and the µ2-EGFP chimera integrated in the endogenous AP-2 complex in COS-7 cells, we performed an immunoprecipitation with anti-alpha chain of AP-2 (Fig. 3A). µ2-EGFP and CD229 coprecipitated with AP-2 endogenous complex (second and third lanes, respectively). Moreover, CD229·µ2-EGFP and AP-2 were in a complex (fourth lane). To test whether most µ2-EGFP was free or complexed with the endogenous AP-2, we performed µ2-EGFP transfection in COS-7 cells and immunochemical staining with anti-alpha chain AP-2. The majority of the µ2-EGFP protein colocalized with the endogenous AP-2 (Fig. 3B).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   CD229 binds to µ2 and the endogenous AP-2 complex in COS cells. A, cells transfected with µ2-EGFP, CD229, or both were biotinylated and immunoprecipitated with anti-AP-2alpha . The blot was probed with avidin-POD, anti-GFP, and anti-AP-2alpha . B, cells transfected with µ2-EGFP were fixed and permeabilized, and anti-AP-2alpha staining was carried out. Arrows indicate colocalization of the µ2-EGFP·AP-2alpha endogenous complex.

Tyrosine 470 Is Required for CD229 Binding to µ2-- Analysis of the CD229 sequence revealed several putative motifs for µ2 binding (Y-X-X-phi ) (where X stands for any amino acid and phi  for a bulky hydrophobic residue) (Fig. 4A). A more restricted binding motif has been proposed for µ2: YPPphi , where P represents a polar amino acid (25). Following these criteria we found a suitable motif for the binding (Fig. 4A). The Y470F mutation abolished the interaction between CD229 and µ2 in a yeast system (Fig. 4B). COS cells were transfected with CD229 and µ2-EGFP +/- Fyn. Samples were biotinylated and divided. One set was immunoprecipitated with anti-CD229 and the second with anti-GFP. CD229 was found to interact with µ2 in the absence of phosphorylation, although some binding was found in the triple transfection, maybe because of residual nonphosphorylated CD229 in this sample (Fig. 4C). Moreover, only nonphosphorylated CD229 was found to bind µ2 (anti-GFP immunoprecipitation) in the samples where Fyn was present. Altogether, these data indicate that CD229 interacts with µ2 when the receptor is not phosphorylated, and CD229 phosphorylation by Fyn abrogates the binding of the CD229 to the µ2 subunit.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   CD229Y470 is critical for µ2 binding. A, CD229 cytoplasmic tail showing binding sites for the µ2 subunit of the AP-2 (underlined). B, beta -galactosidase assay measuring the interaction between pBridge CD229WT or pBridge CD229Y470F with pACT2-µ2 in yeast cells in the presence or absence of Fyn activity. The binding of CD229WT and CD229Y470F to SAP was also performed. These data are the mean of duplicates and are representative of three experiments. C, CD229 was cotransfected with µ2 +/- Fyn in COS cells. Samples were divided and immunoprecipitated (Ip) with anti-GFP or anti-CD229 antibody. Avidin-peroxidase, anti-Tyr(P), and anti-GFP blots were performed.

Tyrosine 470 Is Essential for CD229 Endocytosis-- To determine the relevance of CD229-µ2 interaction for receptor internalization, we generated CD229 mutant constructs in which the Tyr470 residue was replaced by phenylalanine or alanine. We transiently transfected CD229 wild-type and mutants encoding constructs into COS-7 and measured their internalization after ligation with anti-CD229 mAb at 37 °C. Thereafter, cells were stripped and stained with CD229 biotinylated antibody plus avidin-PE labeling, and samples were measured by flow cytometry (Fig. 5A). Within 30 min, 30-40% of wild-type CD229 surface receptors had been internalized. In contrast, internalization was completely abrogated, and CD229 surface expression even increased slightly, in CD229 mutants, which Tyr470 had been replaced by phenylalanine or alanine. We also transfected COS cells with the CD229WT and CD229Y470 mutants plus µ2-EGFP. After 24 h, cells were stained with biotinylated antibody at 4 °C followed by avidin-Cy3 at 37 °C (Fig. 5B). In cells transfected with CD229WT, the receptor was internalized and colocalized with the µ2-EGFP, whereas CD229Y470F and CD229Y470A internalization was impaired, and no colocalization with µ2 was found. Both results indicate that Tyr470 is needed for CD229 binding to µ2 and further endocytosis.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   CD229 internalization in COS cells transfected with CD229Y470 mutants is impaired. A, internalization was assessed 30 min after incubation with anti-CD229 at 37 °C and was measured by flow cytometry. These data are the mean of three experiments. B, endocytosis was carried out in CD229WT and CD229 mutants and µ2-EGFP-transfected COS cells. Cells were stained with biotinylated anti-CD229, and avidin-Cy3 was added at 37 °C for 30 min, inducing endocytosis of the receptor. Cells were washed and mounted.

The Cytoplasmic Tail of CD229 Is Associated with the AP-2 Adaptor Complex in T and B Lymphocytes-- Because CD229 is expressed only in cells of the immune system, we next determined whether the association of the AP-2 adaptor complex with CD229 occurred in lymphocytes. To this end, we performed coimmunoprecipitation experiments in two lymphocytic cell lines: Jurkat (T cell line) and Daudi (B cell line). Both cell lines were immunoprecipitated using anti-CD229 mAb and an anti-CD84 as a control mAb. Western blot was probed with anti-AP-2alpha mAb (Fig. 6). A band representing AP-2alpha was found only in the lane in which CD229 was immunoprecipitated. Taken together, these data demonstrate that the AP-2 adaptor complex specifically interacts with the cytoplasmic tail of CD229 in T and B lymphocytes.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   CD229 interacts with the AP-2 complex in T and B lymphocytes. Jurkat and Daudi cell lines were biotinylated and lysed. Anti-CD229 or anti-CD84 as a control Ig was used for immunoprecipitation (ip). The blot was probed with avidin-peroxidase and anti-AP-2alpha .

Anti-CD229 mAbs Trigger CD229 Internalization-- Anti-CD229 mAbs induce the internalization of CD229 in COS cells after 30 min of mAb coligation. Because CD229 is expressed on lymphocytes and associates with the AP-2 complex, we assayed CD229 internalization in these cells. Endocytosis was assayed in the Jurkat T cell line and in the Daudi B cell line. CD229 was endocytosed rapidly in Jurkat cells, reaching a plateau within 15 min. The internalization of CD229 after incubation with intact anti-CD229 was comparable with that obtained with F(ab')2 in Jurkat cells (Fig. 7A). In contrast, internalization of CD229 with intact mAb was impaired in B cells. However, when F(ab')2 was used to coligate, the effect on CD229 internalization resembled that observed in T cells, indicating that CD229 endocytosis may be regulated through Fcgamma receptors (Fig. 7B). In agreement with this observation, a reduction of intact antibody concentration used for ligation induced some CD229 endocytosis in B cells, indicating that a limiting mAb concentration elicits coligation with CD229 with minimal Fcgamma receptor binding (data not shown). The internalization of CD229 after antibody coligation may represent a constitutive turnover rate of CD229 from the cell surface. To distinguish these two events (endocytosis versus turnover), we used cycloheximide and BFA, which block the expression of newly synthesized protein. BFA blockage inhibits the transport of proteins from the endoplasmic reticulum to the Golgi apparatus and also recycling of endocytosed proteins (30-32). Treatment with cycloheximide did not alter CD229 surface expression on T or B cells within the time period assayed for endocytosis (data not shown). Treatment with BFA for 2 h slightly reduced CD229 expression in T cells after 60 min (20-25%) but did not significantly reduce the surface expression of CD229 in B cells (Fig. 7C). The transferrin receptor (CD71), which is rapidly recycled (33), was used as a control. After 15 min, CD71 surface expression was reduced more than 50% in BFA-treated cells (Fig. 7D). Altogether, these results indicate that CD229 expression on the cell surface is more stable on B than on T cells, and in both cases, the rate of turnover is lower than that for CD71.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Ab-dependent internalization of CD229. Kinetics of CD229 internalization using intact (squares) or F(ab')2 (triangles) anti-CD229 mAb is shown in Jurkat T cells (A) and Daudi B cells (B). The percentage of internalization was calculated using MFI values of PE as follows: 100 - (MFI at 37 °C/MFI at 4 °C) × 100. The turnover of cell surface CD229 was studied. Changes in surface expression of CD229 (C) and CD71 (transferrin receptor) as a positive control (D) were assessed after treatment with 10 µg/ml BFA. The percentage of surface expression was calculated by determining the ratio of MFI of treated cells compared with MFI of untreated cells at each time point and extrapolated as a percentage. The data represent the mean of duplicates and are representative of three experiments.

Endocytosed CD229 Mainly Follows the Lysosomal Degradation Pathway-- We next analyzed the events following CD229 ligation in lymphocytes. CD229, once internalized, may traffic to lysosomal vesicles for degradation or be recycled back to the cell surface. To distinguish these two events we assessed CD229 endocytosis in the presence or absence of BFA. If most CD229 were recycled back to the cell surface, the loss of CD229 after mAb ligation would be much greater in the presence of BFA. On the other hand, if most endocytosed CD229 were transferred to lysosomes, we would obtain identical results in the presence or absence of BFA. CD229 surface levels decreased slightly on T cells induced by F(ab')2 anti-CD229 in the presence of BFA, suggesting that CD229 was partially recycled back to the cell surface (20-25%) but mostly trafficked to lysosomal degradation (Fig. 8A). In B cells, CD229 surface levels were similar in both cases. Thus, endocytosed CD229 follows mainly the lysosomal degradation pathway in these cells (Fig. 8B). Taken together, these results suggest that most CD229 is transported to the lysosomal compartment rather than recycled back to the cell surface.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of BFA on Ab-dependent internalization of CD229. Internalization of CD229 in Jurkat T cells (A) and Daudi B cells (B) is shown. Internalization was determined at various times after incubation with F(ab')2 anti-CD229 at 37 °C in the absence (white columns) or presence (black columns) of 10 µg/ml BFA. These data are the mean of duplicates and representative of three experiments.

CD229 Internalization Is Regulated after TCR or BCR Cross-linking-- We next investigated whether antigen receptor cross-linking modulates CD229 internalization in T and B lymphocytes. When we assayed CD229 expression after TCR ligation at 30-60 min, the expression of CD229 did not vary significantly. In contrast, CD229 ligation did not affect CD3 expression in this period (data not shown). Unexpectedly, the coligation of CD229 and TCR enhanced CD229 internalization (Fig. 9A). Daudi cells were incubated with anti-IgM F(ab')2 and anti-CD229 for 30 min, and CD229 endocytosis was studied. CD229 internalization after IgM coligation was enhanced (Fig. 9B).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of TCR and BCR coligation in CD229 endocytosis. A, Jurkat cells were incubated with medium with anti-CD229 for 30 min (a), preincubated with 1 µg/ml anti-CD3 for 5 min (b), and anti-CD229 was added for 30 min (c). B, Daudi cells were incubated with medium with anti-CD229 for 30 min (d), preincubated with 20 µg/ml anti-IgM F(ab')2 (e), and cells were incubated with anti-CD229 for 30 min (f). Cells were stripped, and CD229 staining was performed (solid lines). Control Ig staining was also performed (dotted lines). CD229 internalization (%) was measured after various stimuli for 30 min in Jurkat (C) and Daudi cells (D). These data are the mean of duplicates and representative of three experiments.

Taken together, these data suggest that signals delivered by the TCR and BCR regulate CD229 cell surface expression.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we have shown that CD229 binds to the µ2 chain of the AP-2 complex. It is well established that the µ2 subunit binds to the consensus sorting signal NPXY or YPPphi (25). Although it has been suggested that µ2 interacts with dileucine motifs (34), peptides containing dileucine motifs bind only to the beta  subunit of AP1 and AP-2 complexes and not to the other subunits (35, 36). Analysis of CD229 revealed only one sequence that follows the YPPphi consensus (Y470EKL), which is conserved in mouse (37). Using site-directed mutagenesis, we mapped the µ2 interaction to CD229 in this motif. The single replacement of tyrosine by phenylalanine abrogates µ2 binding to CD229 in yeast. It has been proposed that the hydroxyl group of tyrosine contributes to a network of interactions with µ2 residues that form the hydrophobic pocket, explaining why phenylalanine does not efficiently replace tyrosine in YPPphi signals (38, 39). As expected, the recruitment of SAP in the mutant is not altered because both molecules do not compete for the same motif (7). CD229 binds to µ2 when Fyn is active, or kinase activity of Fyn is completely abrogated by depletion of its catalytic region in the yeast system. This suggests various possibilities: CD229-µ2 interaction occurs when Tyr470 is phosphorylated, or phosphorylation of the CD229 tail is partial, allowing the screening of interactions dependent and independent of phosphorylation at the same time. Our results point to this last possibility because the CD229-µ2 interaction only occurred when the receptor was not phosphorylated. This agrees with literature data, which show that this type of interactions does not depend on phosphorylation. The crystal structure of µ2 indicates that phosphotyrosine does not fit into its hydrophobic pocket (40).

We have also demonstrated that the cytoplasmic tail of CD229 but not that of any of the other members of CD150 family can interact with the AP-2 complex via its µ2 chain. This intriguing difference suggests that the expression and internalization of CD229 are tightly and differentially regulated. The structure of CD229 differs from that of the rest of the CD150 family of receptors. It is the only member that has four extracellular Ig-like domains, and it has the longest cytoplasmic tail, comprising 180 amino acids, 16 threonines, 17 serines, and 8 tyrosines. Two unique tyrosine-based motifs (with the consensus amino acid sequence TV/I YXXV/I) are critical for the binding to the SAP/SH2D1a protein and the Eat-2 SH2 domain protein homolog to SAP in B cells (41).

Furthermore, CD229 can bind to endogenous AP-2 in COS cells, µ2-EGFP chimera can efficiently integrate in the endogenous AP-2 complex, and CD229 can coprecipitate with µ2-EGFP and the AP-2 endogenous complex. The complex is functional because CD229 internalization and CD229·µ2-EGFP colocalization were detected in COS cells after antibody-induced endocytosis. In agreement with our mapping data, CD229Y470F and CD229Y470A endocytosis was severely impaired. Although in our model a phenylalanine substitution abrogates the binding to µ2, the FXXphi motif can fit into the hydrophobic pocket of µ2 (42) but leads to a weaker interaction and slower endocytosis. Thus, Tyr470 is essential for CD229 endocytosis and may inhibit the internalization of this receptor after its phosphorylation in vivo. CD229 can be phosphorylated by Src-kinase Fyn in COS cells, and its possible interaction with a SH2 domain protein may further regulate the signaling and trafficking of the molecule, as proposed for CTLA-4 (43).

Because CD229 is expressed in T and B lymphocytes, we have defined the mechanism of CD229 internalization and demonstrated that it can be regulated differentially in T and B cell lines. CD229 was endocytosed rapidly in response to antibody ligation in Jurkat T cells, whereas no internalization was observed in B cells. The same results were obtained in lymphocytes from peripheral blood. CD229 in B cells was inhibited by the Fcgamma receptor coligation because F(ab')2 antibodies induce CD229 endocytosis in B cells. The CD229 uptake rate was similar using the intact and F(ab')2 antibodies in Jurkat cells lacking Fcgamma receptors. In agreement with our results, the coligation of Fcgamma receptors and BCR has been suggested to inhibit endocytosis by blocking the processing and presentation of the BCR-bound antigen (44). Using BFA and cycloheximide, we have determined that CD229, unlike transferrin receptor (CD71), exhibits a low constitutive rate of turnover, and therefore, the rapid internalization of CD229 represents ligand-induced endocytosis. After endocytosis, CD229 was segregated into two distinguishable pools, one that is shuttled to a nonrecycling degradation pathway and another that is recycled to the cell surface. The results suggest that ~75-80% of CD229 in T cells become degraded via lysosomal compartments, and the remaining 20-25% of complexes are recycled to the cell surface. In contrast, most CD229 is trafficked to the lysosomal degradation pathway in B cells.

Moreover, TCR and anti-IgM coligation enhances CD229 endocytosis, suggesting that the antigen receptor signaling regulates the availability of CD229 at the plasma membrane. Thus, endocytosis may represent a critical mechanism that modulates CD229 cell surface expression rapidly. After TCR activation, phosphatidylinositol 3-kinase may become activated and catalyze the conversion of phosphatidylinositol 4,5-biphosphate to phosphatidylinositol 3,4,5-trisphosphate. The pleckstrin homology domain in the alpha 2 subunit of the AP-2 adaptor complex binds with high affinity to phosphatidylinositol 3,4,5-trisphosphate. This binding mediates two effects: localization of AP-2 in the membrane and increase in the affinity of µ2 binding to endocytosis sorting signals (45, 46).

Because CD229 endocytosis is impaired when Fcgamma receptors are triggered and enhanced when the BCR is activated, this molecule may have a differential role in these different events. The ability to regulate CD229 internalization in T and B cells differentially may allow for different net effects of CD229 signaling which may be cell-specific. Recent studies indicate that CD229, unlike CD150 and CD84, inhibits interferon-gamma secretion after TCR activation in T cells.2 TCR and BCR may increase the rate of CD229 endocytosis to prevent CD229 from delivering negative signals to the cell and Fcgamma receptor ligation retains the CD229 on the cell surface, thus favoring signaling through this receptor and the maintenance of an inhibitory response. The development of CD229 knock-out mice may be a key step to define the physiological role of CD229.

    ACKNOWLEDGEMENT

We thank Joan Sayós for a critical review of this manuscript.

    FOOTNOTES

* This work was supported in part by Grants SAF00-037 and FISS 02/3056 from the Comisión Interministerial de Ciencia y Tecnología.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a MAE/AECI fellowship from the Ministerio de Asuntos Exteriores, Spain.

§ To whom correspondence should be addressed: Unidad de Inmunología, Departamento Biología Celular, Facultad de Medicina. C/Casanova 143, Barcelona E-08036, Spain. Tel.: 34-93-227-5400 (ext. 2338); Fax: 34-93-451-5272; E-mail: mmartin@medicina.ub.es.

Published, JBC Papers in Press, March 5, 2003, DOI 10.1074/jbc.M301569200

2 J. M. Del Valle, P. Engel, and M. Martín, unpublished result.

    ABBREVIATIONS

The abbreviations used are: SAP, SLAM-associated protein; PE, R-phycoerythrin; TCR, T cell receptor(s); BCR, B cell receptor(s); BFA, brefeldin A; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; EGFP, enhanced green fluorescent protein; GFP, green fluorescent protein; mAb, monoclonal antibody; MFI, mean fluorescence intensity; WT, wild-type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. de la Fuente, M. A., Tovar, V., Villamor, N., Zapater, N., Pizcueta, P., Campo, E., Bosch, J., and Engel, P. (2001) Blood 97, 3513-3520[Abstract/Free Full Text]
2. Morra, M., Howie, D., Grande, M. S., Sayos, J., Wang, N., Wu, C., Engel, P., and Terhorst, C. (2001) Annu. Rev. Immunol. 19, 657-682[CrossRef][Medline] [Order article via Infotrieve]
3. Sidorenko, S. P., and Clark, E. A. (2003) Nat. Immunol. 4, 19-24[CrossRef][Medline] [Order article via Infotrieve]
4. Sayos, J., Wu, C., Morra, M., Wang, N., Zhang, X., Allen, D., van Schaik, S., Notarangelo, L., Geha, R., Roncarolo, M. G., Oettgen, H., de Vries, J. E., Aversa, G., and Terhorst, C. (1998) Nature 395, 462-469[CrossRef][Medline] [Order article via Infotrieve]
5. Sayos, J., Nguyen, K. B., Wu, C., Stepp, S. E., Howie, D., Schatzle, J. D., Kumar, V., Biron, C. A., and Terhorst, C. (2000) Int. Immunol. 12, 1749-1757[Abstract/Free Full Text]
6. Tangye, S. G., Lazetic, S., Woollatt, E., Sutherland, G. R., Lanier, L. L., and Phillips, J. H. (1999) J. Immunol. 162, 6981-6985[Abstract/Free Full Text]
7. Sayos, J., Martin, M., Chen, A., Simarro, M., Howie, D., Morra, M., Engel, P., and Terhorst, C. (2001) Blood 97, 3867-3874[Abstract/Free Full Text]
8. Peck, S. R., and Ruley, H. E. (2000) Immunogenetics 52, 63-72[CrossRef][Medline] [Order article via Infotrieve]
9. Tovar, V., Del Valle, J., Zapater, N., Martin, M., Romero, X., Pizcueta, P., Bosch, J., Terhorst, C., and Engel, P. (2002) Immunogenetics 54, 394-402[CrossRef][Medline] [Order article via Infotrieve]
10. Coffey, A. J., Brooksbank, R. A., Brandau, O., Oohashi, T., Howell, G. R., Bye, J. M., Cahn, A. P., Durham, J., Heath, P., Wray, P., Pavitt, R., Wilkinson, J., Leversha, M., Huckle, E., Shaw-Smith, C. J., Dunham, A., Rhodes, S., Schuster, V., Porta, G., Yin, L., Serafini, P., Sylla, B., Zollo, M., Franco, B., Bolino, A., Seri, M., Lanyi, A., Davis, J. R., Webster, D., Harris, A., Lenoir, G., de St. Basile, G., Jones, A., Behloradsky, B. H., Achatz, H., Murken, J., Fassler, R., Sumegi, J., Romeo, G., Vaudin, M., Ross, M. T., Meindl, A., and Bentley, D. R. (1998) Nat. Genet. 20, 129-135[CrossRef][Medline] [Order article via Infotrieve]
11. Morra, M., Silander, O., Calpe, S., Choi, M., Oettgen, H., Myers, L., Etzioni, A., Buckley, R., and Terhorst, C. (2001) Blood 98, 1321-1325[Abstract/Free Full Text]
12. Arico, M., Imashuku, S., Clementi, R., Hibi, S., Teramura, T., Danesino, C., Haber, D. A., and Nichols, K. E. (2001) Blood 97, 1131-1133[Abstract/Free Full Text]
13. Wu, C., Nguyen, K. B., Pien, G. C., Wang, N., Gullo, C., Howie, D., Rodriguez-Sosa, M., Edwards, M. J., Borrow, P., Satoskar, A. R., Sharpe, A. H., Biron, C. A., and Terhorst, C. (2001) Nat. Immunol. 2, 410-414[Medline] [Order article via Infotrieve]
14. Crotty, S., Kersh, E. N., Cannons, J., Schwartzberg, P. L., and Ahmed, R. (2003) Nature 421, 282-287[CrossRef][Medline] [Order article via Infotrieve]
15. Sandrin, M. S., Gumley, T. P., Henning, M. M., Vaughan, H. A., Gonez, L. J., Trapani, J. A., and McKenzie, I. F. (1992) J. Immunol. 149, 1636-1641[Abstract/Free Full Text]
16. Martin, M., Romero, X., de la Fuente, M. A., Tovar, V., Zapater, N., Esplugues, E., Pizcueta, P., Bosch, J., and Engel, P. (2001) J. Immunol. 167, 3668-3676[Abstract/Free Full Text]
17. Valiante, N. M., and Trinchieri, G. (1993) J. Exp. Med. 178, 1397-1406[Abstract]
18. Nakajima, H., Cella, M., Langen, H., Friedlein, A., and Colonna, M. (1999) Eur. J. Immunol. 29, 1676-1683[CrossRef][Medline] [Order article via Infotrieve]
19. Aversa, G., Carballido, J., Punnonen, J., Chang, C. C., Hauser, T., Cocks, B. G., and de Vries, J. E. (1997) Immunol. Cell Biol. 75, 202-205[Medline] [Order article via Infotrieve]
20. Cocks, B. G., Chang, C. C., Carballido, J. M., Yssel, H., de Vries, J. E., and Aversa, G. (1995) Nature 376, 260-263[CrossRef][Medline] [Order article via Infotrieve]
21. Carballido, J. M., Aversa, G., Kaltoft, K., Cocks, B. G., Punnonen, J., Yssel, H., Thestrup-Pedersen, K., and de Vries, J. E. (1997) J. Immunol. 159, 4316-4321[Abstract]
22. Castro, A. G., Hauser, T. M., Cocks, B. G., Abrams, J., Zurawski, S., Churakova, T., Zonin, F., Robinson, D., Tangye, S. G., Aversa, G., Nichols, K. E., de Vries, J. E., Lanier, L. L., and O'Garra, A. (1999) J. Immunol. 163, 5860-5870[Abstract/Free Full Text]
23. Bottino, C., Falco, M., Parolini, S., Marcenaro, E., Augugliaro, R., Sivori, S., Landi, E., Biassoni, R., Notarangelo, L. D., Moretta, L., and Moretta, A. (2001) J. Exp. Med. 194, 235-246[Abstract/Free Full Text]
24. Kumaresan, P. R., Lai, W. C., Chuang, S. S., Bennett, M., and Mathew, P. A. (2002) Mol. Immunol. 39, 1-8[CrossRef][Medline] [Order article via Infotrieve]
25. Kirchhausen, T. (1999) Annu. Rev. Cell Dev. Biol. 15, 705-732[CrossRef][Medline] [Order article via Infotrieve]
26. Kirchhausen, T. (2002) Cell 109, 413-416[Medline] [Order article via Infotrieve]
27. Collins, B. M., McCoy, A. J., Kent, H. M., Evans, P. R., and Owen, D. J. (2002) Cell 109, 523-535[Medline] [Order article via Infotrieve]
28. Cefai, D., Schneider, H., Matangkasombut, O., Kang, H., Brody, J., and Rudd, C. E. (1998) J. Immunol. 160, 2223-2230[Abstract/Free Full Text]
29. Poy, F., Yaffe, M. B., Sayos, J., Saxena, K., Morra, M., Sumegi, J., Cantley, L. C., Terhorst, C., and Eck, M. J. (1999) Mol. Cell 4, 555-561[Medline] [Order article via Infotrieve]
30. Wood, S. A., Park, J. E., and Brown, W. J. (1991) Cell 67, 591-600[Medline] [Order article via Infotrieve]
31. Lippincott-Schwartz, J., Yuan, L., Tipper, C., Amherdt, M., Orci, L., and Klausner, R. D. (1991) Cell 67, 601-616[Medline] [Order article via Infotrieve]
32. Chardin, P., and McCormick, F. (1999) Cell 97, 153-155[Medline] [Order article via Infotrieve]
33. Liu, H., Rhodes, M., Wiest, D. L., and Vignali, D. A. (2000) Immunity 5, 665-675
34. Bremnes, T., Lauvrak, V., Lindqvist, B., and Bakke, O. (1998) J. Biol. Chem. 273, 8638-8645[Abstract/Free Full Text]
35. Marks, M. S., Woodruff, L., Ohno, H., and Bonifacino, J. S. (1996) J. Cell Biol. 135, 341-354[Abstract]
36. Rapoport, I., Chen, Y. C., Cupers, P., Shoelson, S. E., and Kirchhausen, T. (1998) EMBO J. 17, 2148-2155[Abstract/Free Full Text]
37. Tovar, V., de la Fuente, M. A., Pizcueta, P., Bosch, J., and Engel, P. (2000) Immunogenetics 51, 788-793[CrossRef][Medline] [Order article via Infotrieve]
38. Trowbridge, I. S., Collawn, J. F., and Hopkins, C. R. (1993) Annu. Rev. Cell Biol. 9, 129-161[CrossRef][Medline] [Order article via Infotrieve]
39. Sauter, M. M., Pelchen-Matthews, A., Bron, R., Marsh, M., LaBranche, C. C., Vance, P. J., Romano, J., Haggarty, B. S., Hart, T. K., Lee, W. M., and Hoxie, J. A. (1996) J. Cell Biol. 132, 795-811[Abstract]
40. Owen, D. J., and Evans, P. R. (1998) Science 282, 1327-1332[Abstract/Free Full Text]
41. Morra, M., Lu, J., Poy, F., Martin, M., Sayos, J., Calpe, S., Gullo, C., Howie, D., Rietdijk, S., Thompson, A., Coyle, A. J., Denny, C., Yaffe, M. B., Engel, P., Eck, M. J., and Terhorst, C. (2001) EMBO J. 20, 5840-5852[Abstract/Free Full Text]
42. Marsh, B. J., Alm, R. A., McIntosh, S. R., and James, D. E. (1995) J. Cell Biol. 130, 1081-1091[Abstract]
43. Shiratori, T., Miyatake, S., Ohno, H., Nakaseko, C., Isono, K., Bonifacino, J. S., and Saito, T. (1997) Immunity 6, 583-589[Medline] [Order article via Infotrieve]
44. Minskoff, S. A., Matter, K., and Mellman, I. (1998) J. Immunol. 161, 2079-2083[Abstract/Free Full Text]
45. Rapoport, I., Miyazaki, M., Boll, W., Duckworth, B., Cantley, L. C., Shoelson, S., and Kirchhausen, T. (1997) EMBO J. 16, 2240-2250[Abstract/Free Full Text]
46. Jost, M., Simpson, F., Kavran, J. M., Lemmon, M. A., and Schmid, S. L. (1998) Curr. Biol. 8, 1399-1402[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.